MCM
VCYT icon

Moore Capital Management’s Veracyte VCYT Stock Holding History

Moore Capital Management’s Portfolio VCYT Stock Details VCYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.57M Buy
79,760
+36,995
+87% +$1.37M 0.05% 244
2025
Q4 		$1.8M Buy
+42,765
New +$1.72M 0.03% 393

Other funds holding VCYT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Moore Capital Management's VCYT Position: Q1 2026 in Review

Moore Capital Management increased its Veracyte (VCYT) stake by 87% in Q1 2026, buying an estimated $1.37M and bringing the position to 79,760 shares worth $2.57M. The position accounts for 0.05% of the portfolio, ranked #244.

Moore Capital Management first reported a position in VCYT in Q4 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • Moore Capital Management held 79,760 shares of Veracyte worth $2.57M as of Q1 2026.
  • Moore Capital Management bought 36,995 Veracyte shares in Q1 2026, an estimated $1.37M.
  • Veracyte made up 0.05% of Moore Capital Management's portfolio in Q1 2026, its #244 holding.
  • Moore Capital Management first reported a position in Veracyte in Q4 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.